SCHEMBL24427247

SCHEMBL24427247

Cc1nc(Cl)c(-c2ccnc(N)c2)[nH]1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DYRK1A Q13627 6/20 0.43
▸ TLR9 Q9NR96 1/20 0.42
▸ TLR8 Q9NR97 1/20 0.42
▸ TLR7 Q9NYK1 1/20 0.42
▸ KDM4E B2RXH2 1/20 0.42
▸ MEN1 O00255 1/20 0.42
▸ NOS3 P29474 1/20 0.42
▸ NOS1 P29475 1/20 0.42
▸ NOS2 P35228 1/20 0.42
▸ KMT2A Q03164 1/20 0.42
▸ ROCK1 Q13464 1/20 0.41
▸ PIK3C3 Q8NEB9 1/20 0.39
▸ MET P08581 1/20 0.38
▸ BUB1 O43683 1/20 0.38
▸ KCNH2 Q12809 1/20 0.38
▸ PIM1 P11309 1/20 0.38
▸ CDK9 P50750 1/20 0.38
▸ DYRK2 Q92630 1/20 0.38
▸ DYRK1B Q9Y463 1/20 0.38
▸ CDC7 O00311 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24427248 0.79 GSK3B (0.40) PIK3C3BUB1AAK1
SCHEMBL24427331 0.76 PIK3CD (0.47) TLR9TLR8TLR7KDM4EMEN1
SCHEMBL24427598 0.75 KDM4E (0.42) KDM4EMEN1KMT2AMAPT
SCHEMBL24427633 0.74 PIK3C3 (0.51) PIK3C3TGFBR1TGFBR2
SCHEMBL24428046 0.73 PIK3CD (0.36) TLR8TLR7KDM4EMAPT
SCHEMBL24427588 0.72 NOS3 (0.43) NOS3NOS1NOS2PDPK1
SCHEMBL15676783 0.72 MAP4K4 (0.42) TGFBR1TGFBR2
SCHEMBL24427587 0.71 SMN1; SMN2 (0.36) TLR9TLR8TLR7KDM4ETGFBR1
SCHEMBL15676695 0.71 PDPK1 (0.52) ROCK1TGFBR1PDPK1
SCHEMBL18774003 0.70 TGFBR1 (0.34) TGFBR1TGFBR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11518766-B2 Tricyclic compound, preparation method therefor and use thereof SHANGHAI JEMINCARE PHARMACEUTICALS CO., LTD. (CN) 2022-12-06 — — US disclosed
EP-3998263-A1 TRICYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF Shanghai Jemincare Pharmaceuticals Co., Ltd. (CN) 2022-05-18 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11518766-B2 Tricyclic compound, preparation method therefor and use thereof TFPI, TFPI2, F11 DYRK1A 3237/4885TLR9 4672/4885TLR8 3476/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback